31 Jan 2019 07:00
SalvaRx Group plc
("SalvaRx" or the "Company")
Change of Nominated Adviser and Broker
SalvaRx (AIM: SALV), the drug discovery and development company focused on cancer immunotherapy, announces that pursuant to the proposed merger between SP Angel Corporate Finance LLP ("SP Angel") and Northland Capital Partners Ltd, it has appointed SP Angel as its Nominated Adviser and Joint Broker with immediate effect.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Enquiries:
SalvaRx Group plc | |
Denham Eke, Chief Financial Officer | Tel: +44 (0) 01624 639396 |
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker | Tel: +44 (0) 20 3470 0470
|
Matthew Johnson / Lindsay Mair (Corporate Finance) | |
Peterhouse Capital Limited Joint Broker Lucy Williams / Duncan Vasey | Tel: +44 (0) 20 7469 0932 |
SALV.L (SALV)